Viking Therapeutics, Inc. current report, 23 May 2019

Full document

Business Context and Reporting Period

This Form 8-K reports on the 2019 Annual Meeting of Stockholders for Viking Therapeutics, Inc., held on May 23, 2019. The company is an emerging growth company incorporated in Delaware with its principal executive offices in San Diego, California. As of the record date (April 1, 2019), 72,027,657 shares of common stock were issued and outstanding.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results rather than financial performance.

Material Changes and Voting Results

The stockholders voted on two proposals at the Annual Meeting:

  • Proposal 1: Election of Class I Director Nominees
    • Matthew W. Foehr: Elected with 20,855,118 votes for, 5,041,676 votes withheld, and 31,117,210 broker non-votes.
    • Charles A. Rowland, Jr.: Elected with 18,612,432 votes for, 7,284,362 votes withheld, and 31,117,210 broker non-votes.
    • Both directors were elected to serve until the 2022 Annual Meeting.
  • Proposal 2: Ratification of Independent Registered Public Accounting Firm
    • Marcum LLP was ratified as the independent auditor for the fiscal year ending December 31, 2019.
    • Voting Results: 55,684,813 votes for, 999,154 votes against, 330,037 abstentions, and 0 broker non-votes.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves solely to disclose the outcomes of the shareholder vote.

Key Facts for Investor Verification

  • Confirmation of the election of Matthew W. Foehr and Charles A. Rowland, Jr. to the Board of Directors.
  • Verification of Marcum LLP's appointment as the independent auditor for fiscal year 2019.
  • Review of the definitive proxy statement filed on April 5, 2019, for detailed background on the proposals.
  • Assessment of the significant number of broker non-votes (31,117,210) recorded for the director elections.